Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DEGARELIX ACETATE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (L02B, L02BX) — coverage varies; not interchangeable

  • Abiraterone (Zytiga): general benefit
  • Anastrozole (Arimidex): general benefit
  • Bicalutamide (Casodex): general benefit, Not a benefit
  • Exemestane (Aromasin): general benefit
  • Flutamide (Euflex): general benefit, Not a benefit
  • Fulvestrant (Faslodex): general benefit

3 more in the class list below

Firmagon · DIN 02337029 · 80mg · Pd for injection-vial

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Firmagon · DIN 02337029 Manufacturer: Ferring Inc.; listing date 2011-03-15 Health Canada: Marketed since 2009-11-24 · brand FIRMAGON · ATC L02BX02 DEGARELIX, L02BX02 DEGARELIX · form Powder for solution · route Subcutaneous · ingredients DEGARELIX (DEGARELIX ACETATE) 80 MG/VIAL · company Ferring inc · schedule Prescription
Check this DIN again · Health Canada product record

Firmagon: Formulary list price $274.1760/unit (unit not stated in source; not the patient's cost)

Ministry pays: $274.1760 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82263 · Verify on the e-Formulary ↗ (DIN 02337029)

Source record
DIN 02337029: Firmagon Raw flags: sec3=Y Item: 100000198; group id 155; item number 0265; lccId None; manufacturer id FEI Source form: Pd for Inj-Vial Pk; strength: 80mg Recorded listing: General benefit Source prices (unrounded): $274.1760; ministry $274.1760 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02337029 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82263
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02337029
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Firmagon · DIN 02337037 · 120mg · Pd for injection-vial

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Firmagon · DIN 02337037 Manufacturer: Ferring Inc.; listing date 2011-03-15 Health Canada: Marketed since 2009-11-24 · brand FIRMAGON · ATC L02BX02 DEGARELIX, L02BX02 DEGARELIX · form Powder for solution · route Subcutaneous · ingredients DEGARELIX (DEGARELIX ACETATE) 120 MG/VIAL · company Ferring inc · schedule Prescription
Check this DIN again · Health Canada product record

Firmagon: Formulary list price $370.9440/unit (unit not stated in source; not the patient's cost)

Ministry pays: $370.9440 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82264 · Verify on the e-Formulary ↗ (DIN 02337037)

Source record
DIN 02337037: Firmagon Raw flags: sec3=Y Item: 100000199; group id 155; item number 0266; lccId None; manufacturer id FEI Source form: Pd for Inj-Vial Pk; strength: 120mg Recorded listing: General benefit Source prices (unrounded): $370.9440; ministry $370.9440 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02337037 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82264
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02337037
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

EXEMESTANE

· 3 products · General benefit · strengths: 25mg · Tab

FLUTAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab

FULVESTRANT

· 6 products · General benefit · strengths: 50mg/mL · Inj Sol

LETROZOLE

· 20 products · General benefit · strengths: 2.5mg · Tab

TAMOXIFEN CITRATE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 10mg, 20mg · Tab

ENZALUTAMIDE

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg · Cap

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE FIRMAGON® (degarelix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist (blocker) indicated for testosterone suppression in patients with advanced hormone-dependent prostate cancer in whom androgen deprivation is warranted. Approval of FIRMAGON for prostate cancer is based on testosterone suppression to castrate levels. Evidence of palliation or prolongation of survival has not been established for FIRMAGON in prostate cancer. Geriatrics (>65 years of age) The patient population tested in the clinical program was typical of the intended target population of patients with prostate cancer. The mean age was 74 years (range 47 to 98 years), with 82% age 65 and over and 42% age 75 and over. Pediatrics (<18 years of age) FIRMAGON is not indicated in pediatric patients. Women (>18 years of age) FIRMAGON is not indicated for use in women. Pr FIRMAGON® Page 3 of 46 https://pdf.hres.ca/dpd_pm/00034229.PDF PM date: March 18, 2016 Source product: FIRMAGON; DIN 02337029; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.